Tags

Type your tag names separated by a space and hit enter

Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
Dermatol Ther. 2012 Nov-Dec; 25(6):615-8.DT

Abstract

Meglumine antimoniate compounds have been the mainstay of treatment for cutaneous leishmaniasis (CL) for decades. We propose to evaluate the place of these drugs in this indication in Tunisia. We retrospectively reviewed medical records of 67 patients treated for (CL) using meglumine antimoniate at a dose of 20 mg/kg/day for 15 day from 1998 to 2010. Clinical and laboratory data, tolerance, and outcome were precised. Side effects were recorded in 17 among 67 patients (25%). The average age was 44.4 years (2-86 years). Antimony intolerance events occurred in 11 patients, stibio-intoxication events in nine cases, and the both type of antimony adverse effects were observed in three patients. Fever was the most frequent complication of antimony intolerance (five cases), followed by cough (three cases), rash (two cases), injection site erythema (two cases), musculoskeletal pain (one case), asthenia (one case), and vomiting (one case). Signs of stibio-intoxication were asymptomatic elevation of amylase level (four cases), hepatic cytolysis (three cases), hematologic toxicity (three cases), and acute toxic kidney failure (one case). Meglumine antimoniate was stopped in 13 cases. Systemic administration of pentavalent antimonials in the treatment of CL has been associated with severe adverse effects. CL observed in Tunisia is a self-healing dermatosis that never induces sequela; therefore, other therapies such as topical treatment or cryotherapy should be considered.

Authors+Show Affiliations

Dermatology Department, Habib Thameur Hospital, Tunis, Tunisia. rym.benmously@rns.tnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23210761

Citation

Mlika, Rym Benmously, et al. "Should We Continue to Indicate Meglumine Antimoniate as First-line Treatment for Cutaneous Leishmaniasis in Tunisia." Dermatologic Therapy, vol. 25, no. 6, 2012, pp. 615-8.
Mlika RB, Hamida MB, Hammami H, et al. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia. Dermatol Ther. 2012;25(6):615-8.
Mlika, R. B., Hamida, M. B., Hammami, H., Jannet, S. B., Badri, T., Fenniche, S., & Mokhtar, I. (2012). Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia. Dermatologic Therapy, 25(6), 615-8. https://doi.org/10.1111/j.1529-8019.2012.01522.x
Mlika RB, et al. Should We Continue to Indicate Meglumine Antimoniate as First-line Treatment for Cutaneous Leishmaniasis in Tunisia. Dermatol Ther. 2012 Nov-Dec;25(6):615-8. PubMed PMID: 23210761.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia. AU - Mlika,Rym Benmously, AU - Hamida,Myriam Ben, AU - Hammami,Houda, AU - Jannet,Salima Ben, AU - Badri,Talel, AU - Fenniche,Sami, AU - Mokhtar,Inçaf, PY - 2012/12/6/entrez PY - 2012/12/6/pubmed PY - 2013/5/29/medline SP - 615 EP - 8 JF - Dermatologic therapy JO - Dermatol Ther VL - 25 IS - 6 N2 - Meglumine antimoniate compounds have been the mainstay of treatment for cutaneous leishmaniasis (CL) for decades. We propose to evaluate the place of these drugs in this indication in Tunisia. We retrospectively reviewed medical records of 67 patients treated for (CL) using meglumine antimoniate at a dose of 20 mg/kg/day for 15 day from 1998 to 2010. Clinical and laboratory data, tolerance, and outcome were precised. Side effects were recorded in 17 among 67 patients (25%). The average age was 44.4 years (2-86 years). Antimony intolerance events occurred in 11 patients, stibio-intoxication events in nine cases, and the both type of antimony adverse effects were observed in three patients. Fever was the most frequent complication of antimony intolerance (five cases), followed by cough (three cases), rash (two cases), injection site erythema (two cases), musculoskeletal pain (one case), asthenia (one case), and vomiting (one case). Signs of stibio-intoxication were asymptomatic elevation of amylase level (four cases), hepatic cytolysis (three cases), hematologic toxicity (three cases), and acute toxic kidney failure (one case). Meglumine antimoniate was stopped in 13 cases. Systemic administration of pentavalent antimonials in the treatment of CL has been associated with severe adverse effects. CL observed in Tunisia is a self-healing dermatosis that never induces sequela; therefore, other therapies such as topical treatment or cryotherapy should be considered. SN - 1529-8019 UR - https://www.unboundmedicine.com/medline/citation/23210761/Should_we_continue_to_indicate_meglumine_antimoniate_as_first_line_treatment_for_cutaneous_leishmaniasis_in_Tunisia_ L2 - https://doi.org/10.1111/j.1529-8019.2012.01522.x DB - PRIME DP - Unbound Medicine ER -